EAN 2021 | Which treatment is optimal for migraine prevention?
Recent years have seen exciting growth in the number of effective agents available for the preventive treatment of migraine. Dimos-Dimitrios Mitsikostas, MD, PhD, National & Kapodistrian University of Athens, Athens, Greece, addresses how these new treatments can be tailored into an individualized treatment plan now that there are numerous options available. Prof. Mitsikostas emphasizes the importance of consulting with patients on their individual needs and concerns in order to find the best-suited regimen for their lifestyle. This interview took place during the European Academy of Neurology 2021 congress.
Disclosures
Prof. Mitsikostas reports the following disclosures:
Research and traveling grants, honoraria and consultation fees from Allergan, Amgen, Biogen, Cefaly, Eli Lily, ElectroCore, Genesis Pharma, Lundbeck, Novartis, Merz, Sanofi, and Teva.
Trials for Cefaly, Eli Lily, ElectroCore, Lundbeck, Novartis, Merz, Sanofi, and Teva.
Associate Editor in the Journal of Headache and Pain.
Co-chair of the Management group of the Headache Scientific Panel at the European Academy of Neurology and President of the Hellenic Headache Society.
